# US 2026/0159465 A1 · Methods of making and using 1-methyleffusol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0159465 A1
- Document ID: US20260159465A1
- Status: Published application
- Kind: A1
- Application number: 19/080,364
- Filed: 2025-03-14
- Published: 2026-06-11
- Earliest claimed: 2024-03-26
- Applicants: Laboratory for Synthetic Chemistry and Chemical Biology Limited
- Inventors: Chi-Ming Che; Kai Yip Lo
- Web page: https://patentgrep.com/patent/US20260159465A1

## CPC

- C07C 37/14: by addition reactions, i.e. reactions involving at least one carbon-to-carbon unsaturated bond
- C07C 41/30: by increasing the number of carbon atoms, e.g. by oligomerisation
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61P 19/10: for osteoporosis
- C07C 37/055: the substituted group being bound to oxygen, e.g. ether group
- C07C 37/18: by condensation involving halogen atoms of halogenated compounds
- C07C 37/68: Purification; separation; Use of additives, e.g. for stabilisation {(C07C37/004 and C07C37/005 take precedence)}
- C07C 39/23: polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
- C07C 41/18: by reactions not forming ether-oxygen bonds
- C07C 41/20: by hydrogenation of carbon-to-carbon double or triple bonds
- C07C 41/22: by introduction of halogens; by substitution of halogen atoms by other halogen atoms
- C07C 41/24: by elimination of halogens, e.g. elimination of HCl
- C07C 41/34: Separation; Purification; Stabilisation; Use of additives
- C07C 2603/26: Phenanthrenes; Hydrogenated phenanthrenes
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of making 1-methyleffusol are described herein. The 1-methyleffusol compound, and pharmaceutical compositions thereof, can be used to stimulate bone forming activities in a subject in need thereof.

## Claims

### Claim 1

A method of making 1,8-dimethyl-4-vinyl-9,10-dihydrophenanthrene-2,7-diol, the method comprising the steps of
(i) refluxing 1-(bromomethyl)-3-methoxy-2-methylbenzene and triphenylphosphine in solution to afford a phosphonium bromide;
(ii) refluxing the phosphonium bromide and 3-methoxy-2-methylbenzaldehyde in an alkaline solution to afford (Z)- and (E)-1,2-bis(3-methoxy-2-methylphenyl)ethene stereoisomers;
(iii) hydrogenating the (Z)- and (E)-1,2-bis(3-methoxy-2-methylphenyl)ethene to afford 1,2-bis(3-methoxy-2-methylphenyl)ethane stereoisomers;
(iv) brominating the 1,2-bis(3-methoxy-2-methylphenyl)ethane to afford 5-bromo-1-methoxy-3-(3-methoxy-2-methylphenethyl)-2-methylbenzene;
(v) oxidatively coupling the 5-bromo-1-methoxy-3-(3-methoxy-2-methylphenethyl)-2-methylbenzene to afford 4-bromo-2,7-dimethoxy-1,8-dimethyl-9,10-dihydrophenanthrene;
(vi) demethylating the 4-bromo-2,7-dimethoxy-1,8-dimethyl-9,10-dihydrophenanthrene to afford 4-bromo-1,8-dimethyl-9,10-dihydrophenanthrene-2,7-diol;
(vii) subjecting the 4-bromo-1,8-dimethyl-9,10-dihydrophenanthrene-2,7-diol to a Suzuki-coupling reaction with a vinyl trifluoroborate salt and a palladium salt to afford 1,8-dimethyl-4-vinyl-9,10-dihydrophenanthrene-2,7-diol; and
(viii) purifying the 1,8-dimethyl-4-vinyl-9,10-dihydrophenanthrene-2,7-diol.

### Claim 2 (depends on 1)

The method of claim 1, wherein the refluxing of step (i) occurs in toluene.

### Claim 3 (depends on 1)

The method of claim 1, wherein the alkaline solution is an aqueous solution comprising lithium chloride and lithium hydroxide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the hydrogenating of step (iii) comprises reacting the (E)-1,2-bis(3-methoxy-2-methylphenyl)ethene with palladium on charcoal in one or more solvents under a hydrogen gas atmosphere.

### Claim 5 (depends on 1)

The method of claim 1, wherein the brominating of step (iv) occurs by C—H borylation using an iridium(I) catalyst and a boron agent, and subsequent bromination with a bromide salt.

### Claim 6 (depends on 1)

The method of claim 1, wherein the oxidatively coupling of step (v) is carried out in the presence of a hypervalent iodine reagent and a Lewis acid catalyst.

### Claim 7 (depends on 1)

The method of claim 1, wherein the demethylating of step (vi) is carried out in the presence of boron tribromide.

### Claim 8 (depends on 1)

The method of claim 1, wherein the vinyl trifluoroborate salt is potassium vinyltrifluoroborate and/or the palladium salt is Pd(dppf)Cl2.

### Claim 9 (depends on 1)

The method of claim 1, wherein:
the 1,2-bis(3-methoxy-2-methylphenyl)ethane is subjected to purification prior to step (iv);
the 5-bromo-1-methoxy-3-(3-methoxy-2-methylphenethyl)-2-methylbenzene is subjected to purification prior to step (v);
the 4-bromo-2,7-dimethoxy-1,8-dimethyl-9,10-dihydrophenanthrene is subjected to purincation prior to step (vi); and/or
the 4-bromo-1,8-dimethyl-9,10-dihydrophenanthrene-2,7-diol is subjected to purincation prior to step (vii).

### Claim 10 (depends on 1)

The method of claim 1, further comprising a step of forming a pharmaceutically acceptable salt of the purified 1,8-dimethyl-4-vinyl-9,10-dihydrophenanthrene-2,7-diol of step (viii).

### Claim 11

A pharmaceutical composition comprising:
1,8-dimethyl-4-vinyl-9,10-dihydrophenanthrene-2,7-diol or a pharmaceutically acceptable salt thereof; and
one or more pharmaceutically acceptable carriers; and
optionally one or more pharmaceutically acceptable excipients.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the one or more pharmaceutically acceptable carriers are selected from the group consisting of water, ethanol, polyethylene glycol, propylene glycol, chitosan polymers and chitosan derivatives, methylcellulose, and an oil.

### Claim 13 (depends on 15)

The pharmaceutical composition of claim 15, wherein the 1,8-dimethyl-4-vinyl-9,10-dihydrophenanthrene-2,7-diol or pharmaceutically acceptable salt thereof is at a concentration ranging from about 1 μM to about 10 mM, from about 1 μM to about 5 mM, from about 10 M to about 1 mM, or from about 10 μM to about 500 μM of the pharmaceutical composition.

### Claim 14 (depends on 15)

A method of stimulating bone formation comprising administering the pharmaceutical composition of claim 15 to a subject in need thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject has osteoporosis.

### Claim 16 (depends on 14)

The method of claim 14, wherein the pharmaceutical composition is administered to the subject by intranasal administration, oral administration, intramuscular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, or a combination thereof.

### Claim 17 (depends on 14)

The method of claim 14, wherein the 1,8-dimethyl-4-vinyl-9,10-dihydrophenanthrene-2,7-diol, or pharmaceutically acceptable salt, used in the method stimulates or induces alkaline phosphatase (ALP) activity in MC3T3-E1 osteoblasts, as compared to the method in the absence of the 1,8-dimethyl-4-vinyl-9,10-dihydrophenanthrene-2,7-diol or pharmaceutically acceptable salt.

### Claim 18 (depends on 14)

The method of claim 14, wherein the 1,8-dimethyl-4-vinyl-9,10-dihydrophenanthrene-2,7-diol or pharmaceutically acceptable salt used in the method promotes calcium deposition and mineralization in MC3T3-E1 osteoblasts.

### Claim 19 (depends on 18)

The method of claim 18, wherein the method also reduces one or more symptoms of bone loss in the subject, as compared to the method in the absence of the 1,8-dimethyl-4-vinyl-9,10-dihydrophenanthrene-2,7-diol or pharmaceutically acceptable salt.

### Claim 20 (depends on 1)

A compound having a chemical structure of Formula (I):
wherein the compound is synthesized according to the method of claim 1.
